Immune dysfunction in inflammatory bowel disease
- PMID: 17383591
- DOI: 10.1016/j.trsl.2006.11.009
Immune dysfunction in inflammatory bowel disease
Abstract
Ulcerative colitis (UC) and Crohn's disease (CD) are idiopathic inflammatory bowel diseases (IBDs) that are characterized by chronic periods of exacerbation and remission. Research into the immunopathogenesis of IBD adds support to the theory that the disease results from a dysfunctional regulation of the immune system that leads to the polarization of intestinal immune cells toward a Th1 (T helper) response. The immunologic factors that mediate alterations in intestinal homeostasis and the development of intestinal mucosal inflammation have been at the forefront of IBD research. Cytokines, which are important regulators of leukocyte trafficking and apoptotic cell death, have emerged as essential immune molecules in the pathogenesis of IBD. In this study, recent advances in the understanding of the dynamism of cytokines and the consequences for mucosal immunity and inflammation in IBD are discussed. Furthermore, this study highlights the potential use of cytokines, anti-cytokine antibodies, and cytokine-related biologic therapies as novel targets for the treatment of IBD.
Similar articles
-
Signaling for inflammation and repair in inflammatory bowel disease.Rom J Gastroenterol. 2004 Dec;13(4):309-16. Rom J Gastroenterol. 2004. PMID: 15624029 Review.
-
Immunologic and molecular mechanisms in inflammatory bowel disease.Surg Clin North Am. 2007 Jun;87(3):681-96. doi: 10.1016/j.suc.2007.03.005. Surg Clin North Am. 2007. PMID: 17560420 Review.
-
Recent advances in biological therapy for inflammatory bowel disease.Trop Gastroenterol. 2004 Jan-Mar;25(1):9-14. Trop Gastroenterol. 2004. PMID: 15303463 Review.
-
Cytokines in inflammatory bowel disease.Arch Immunol Ther Exp (Warsz). 1998;46(3):143-55. Arch Immunol Ther Exp (Warsz). 1998. PMID: 9704146 Review.
-
Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.Curr Opin Gastroenterol. 2009 Jul;25(4):306-13. doi: 10.1097/MOG.0b013e32832bc627. Curr Opin Gastroenterol. 2009. PMID: 19448533 Review.
Cited by
-
Role of prostanoids in gastrointestinal cancer.J Clin Invest. 2018 Jul 2;128(7):2732-2742. doi: 10.1172/JCI97953. Epub 2018 May 7. J Clin Invest. 2018. PMID: 29733297 Free PMC article. Review.
-
American ginseng suppresses colitis through p53-mediated apoptosis of inflammatory cells.Cancer Prev Res (Phila). 2010 Mar;3(3):339-47. doi: 10.1158/1940-6207.CAPR-09-0116. Epub 2010 Feb 23. Cancer Prev Res (Phila). 2010. PMID: 20179294 Free PMC article.
-
Influence of nonalcoholic fatty liver disease on inflammatory bowel disease hospitalizations in the United States.Ann Gastroenterol. 2023 Nov-Dec;36(6):646-653. doi: 10.20524/aog.2023.0839. Epub 2023 Oct 30. Ann Gastroenterol. 2023. PMID: 38023970 Free PMC article.
-
Anti-inflammatory effects and molecular mechanisms of bioactive small molecule garlic polysaccharide.Front Nutr. 2023 Jan 9;9:1092873. doi: 10.3389/fnut.2022.1092873. eCollection 2022. Front Nutr. 2023. PMID: 36698476 Free PMC article.
-
An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis.Nat Biomed Eng. 2024 Oct;8(10):1243-1265. doi: 10.1038/s41551-023-01136-9. Epub 2023 Dec 4. Nat Biomed Eng. 2024. PMID: 38049469
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical